The rituximab biosimilars market is forecasted to achieve notable growth in the coming few years with a forecast CAGR (compound annual growth rate) of more than 13%, as per The Business Research Company’s market report!

Read More On The Rituximab Biosimilars Market Report 2022 – https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

The Rituximab Biosimilars Market Size In 2022 And Forecast

The global rituximab biosimilars market is expected to grow from $1.77 billion in 2021 to $2.05 billion in 2022 at a compound annual growth rate (CAGR) of 16.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The rituximab biosimilars market is expected to reach $3.42 billion in 2026 at a CAGR of 13.6%.

The rituximab biosimilars market consists of sales of rituximab biosimilars. Biosimilars are pharmaceuticals that are manufactured using cell lines and are similar to biologics.

Request for A Sample Of The Global Rituximab Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3430&type=smp

Rise In The Prevalence Of Non-Hodgkins Lymphoma Is Driving The Growth Of The Rituximab Biosimilars Market

According to the American Cancer Society’s, NHL is the most common cancers in the USA accounting for about 4% of all cancers. About 81,560 people (45,630 males and 35,930 females) are diagnosed with NHL in 2021 in the USA. Thus, growing cases of non-Hodgkin’s lymphoma is predicted to generate high demand for rituximab biosimilars over the forecast period.

Competitive Landscape And The Regional Analysis Of The Rituximab Biosimilars Market

Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Ko. KG, BioXpress Therapeutics SA, and Intas Biopharmaceuticals Ltd.

Additionally, as per TBRC’s research – North America was the largest region in the rituximab biosimilars market in 2021 holding the largest market share and Middle East is expected to be the fastest-growing region in the forecast period.

The Rituximab Biosimilars Global Market Report 2022 covers regional data on key drivers, opportunities, and strategies for the seven major regions of the world that are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the rituximab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The report includes market size and forecast market shares for all the regions and countries with respect to the major players of the rituximab biosimilars market.

Focusing On New Product Development In Collaborations – A Key Trend In The Rituximab Biosimilars Market

The companies operating in the biosimilars are continuously focusing on new product development in collaborations with other companies operating in the industry. Innovations through partnerships are shaping the rituximab biosimilars market.

Rituximab Biosimilars Market Segmentation By The Business Research Company

1) By Application: Non-Hodgkin’s Lymphoma, Chronic Lymhocytic Leukemia, Rheumatoid Arthritis, Others
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels
3) By Route of Administration: Subcutaneous, Intravenous, Molecular Type

Here Are Some Reports Related To The Rituximab Biosimilars Market –
Biosimilars Global Market Report 2022
Biosimilar Hormones Global Market Report 2022
Biosimilar Monoclonal Antibodies Global Market Report 2022

Get In Touch With Us – Call us at:

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

Found this article helpful? Share it on: